Article Per Year (5 Year)
p-Index From 2021 - 2026
2.036
P-Index
This Author published in this journals
All Journal Majalah Farmaseutik Indonesia Natural Research Pharmaceutical Journal (INRPJ) Lumbung Farmasi : Jurnal Ilmu Kefarmasian SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Berdikari : Jurnal Pengabdian kepada Masyarakat Pharmacy Action Journal Jurnal Kabar Masyarakat Inspirasi: Jurnal Pengabdian Masyarakat Seroja Husada: Jurnal Kesehatan Masyarakat
Farisa Luthfiana
Gadjah Mada University
Humanities Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Dentistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Nursing Public Health Social Sciences Veterinary Other

Published : 12 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 12 Documents
Search

 1   2 
DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.
Resistensi Clopidogrel pada Pasien Penyakit Jantung Koroner di Asia Tenggara: Sebuah Narrative Review Luthfiana, Farisa
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 1 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i1.9135

Abstract

Clopidogrel is a commonly used antiplatelet agent for the prevention of thrombotic events in patients with coronary artery disease (CAD), particularly in acute coronary syndrome and after percutaneous coronary intervention. However, interindividual variability in clopidogrel response, known as clopidogrel resistance or high on-treatment platelet reactivity (HPR), is associated with increased risks of adverse cardiovascular outcomes. This issue is especially relevant in Southeast Asia, where genetic and clinical factors may influence drug response.Objective: This narrative review aims to summarize current evidence regarding the mechanisms, prevalence, and clinical implications of clopidogrel resistance in patients with coronary artery disease in Southeast Asia. Methods: A narrative review of peer-reviewed literature was conducted focusing on clopidogrel resistance, platelet reactivity, CYP2C19 genetic polymorphisms, and cardiovascular outcomes in Asian and Southeast Asian populations. Results:Evidence indicates that CYP2C19 loss-of-function alleles are highly prevalent in Southeast Asia, resulting in a substantial proportion of patients classified as intermediate or poor metabolizers. These genetic variants are associated with reduced clopidogrel activation, increased platelet reactivity, and a higher risk of major adverse cardiovascular events, including stent thrombosis and recurrent myocardial infarction. Non-genetic factors such as diabetes mellitus, drug–drug interactions, and medication non-adherence further contribute to clopidogrel resistance. Pharmacogenetic-guided antiplatelet therapy and the use of alternative P2Y12 inhibitors, such as ticagrelor or prasugrel, have shown potential to improve clinical outcomes. Conclusion:Clopidogrel resistance represents a significant clinical challenge among patients with coronary artery disease in Southeast Asia. Integration of pharmacogenetic-guided strategies may enhance the effectiveness of antiplatelet therapy in this region.
Co-Authors Afifah, Aulia Nur Agung Endro Nugroho Anton Hadi Wibowo Apriansyah, Hadi Astiani, Rangki Atmi, Nur Azizah Besin, Cecilia S.M Bulele, Viscaria Kesya Darsono, Michelle Didit Sumardiyanto Fajar Amirulah Fitriani Fitriani Ghassani, Fatiha Azka Ika Puspitasari Islamyah, Azmi Annisa Julaeh, Julaeh Katamang, Eden Eljire Imanuel Khan, Khasif Mahendra, Dimas Akbar Mega Lestari Melani, Inge Tri piter, piter Prima, Sylvia Rizky Ramatillah, Diana Laila Ria Anggraeni Sari, Dini Sari, Dini Permata Sri Endah Susilowati Sukartiningsih, Yulita Suprihanto, Mutiara Thillah S Vivian, Maria Wolo, Mulya Adjaib Riwu Zumaero, Zuni